Newer antiseizure medications for children and adolescents with Dravet syndrome outperformed placebos and reduced seizure frequency by at least…
Articles by Steve Bryson, PhD
Note: This article was updated April 21, 2023, to reflect that Fintepla was originally classified a Schedule IV controlled substance…
A higher single dose of STK-001 will be administered in the U.S.-based Phase 1/2a MONARCH trial that is testing …
New safety and efficacy data from two Phase 1/2a clinical trials testing STK-001, Stoke Therapeutics’ investigational treatment for children…
Restoring the activity of Scn1a — the mouse variant of the gene that often is defective in humans with…
More than 70% of Dravet syndrome (DS) patients demonstrated a reduction in seizure frequency of at least 50% while…
The prevalence of Dravet syndrome in the U.K. is low, with most patients diagnosed before age 18, a large-scale…
An international panel of physicians and caregivers with expertise in Dravet syndrome is recommending genetic testing in children ages…
Treatment for one year or longer with the antiseizure therapy Fintepla (fenfluramine) was shown to have a minimal impact…
Virpax Pharmaceuticals has acquired exclusive worldwide rights from Nanomerics to develop a nasal spray of cannabidiol to treat…